These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 9161657

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Primary PTCA versus thrombolysis with tPA in acute myocardial infarction: a formal cost-effectiveness analysis.
    Müllner M, Paulis M, Nikfardjam M, Domanovits H, Huber K.
    Wien Klin Wochenschr; 1999 Jan 15; 111(1):37-41. PubMed ID: 10067269
    [Abstract] [Full Text] [Related]

  • 23. Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy.
    Brown RE, Henderson RA, Koster D, Hutton J, Simoons ML.
    Eur Heart J; 2002 Jan 15; 23(1):50-8. PubMed ID: 11741362
    [Abstract] [Full Text] [Related]

  • 24. Projected cost-effectiveness of primary angioplasty for acute myocardial infarction.
    Lieu TA, Gurley RJ, Lundstrom RJ, Ray GT, Fireman BH, Weinstein MC, Parmley WW.
    J Am Coll Cardiol; 1997 Dec 15; 30(7):1741-50. PubMed ID: 9385902
    [Abstract] [Full Text] [Related]

  • 25. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R, Fattore G, Gensini G.
    G Ital Cardiol; 1997 Jul 15; 27(7):721-6. PubMed ID: 9303862
    [Abstract] [Full Text] [Related]

  • 26. Cost-effectiveness of interventions to reduce the thrombolytic delay for acute myocardial infarction.
    Kildemoes HW, Kristiansen IS.
    Int J Technol Assess Health Care; 2004 Jul 15; 20(3):368-74. PubMed ID: 15446768
    [Abstract] [Full Text] [Related]

  • 27. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
    Kaul P, Armstrong PW, Cowper PA, Eisenstein EL, Granger CB, Van de Werf F, Mark DB.
    Am Heart J; 2005 Apr 15; 149(4):637-44. PubMed ID: 15990746
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
    Mahoney EM, Wang K, Arnold SV, Proskorovsky I, Wiviott S, Antman E, Braunwald E, Cohen DJ.
    Circulation; 2010 Jan 05; 121(1):71-9. PubMed ID: 20026770
    [Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.
    Naylor CD, Bronskill S, Goel V.
    Can J Cardiol; 1993 Jan 05; 9(6):553-8. PubMed ID: 8221354
    [No Abstract] [Full Text] [Related]

  • 30. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W, Pierre K, Massel D.
    Can J Cardiol; 2005 Apr 05; 21(5):423-31. PubMed ID: 15861260
    [Abstract] [Full Text] [Related]

  • 31. Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice.
    Menown I, Montalescot G, Pal N, Fidler C, Orme M, Gillard S.
    Adv Ther; 2010 Mar 05; 27(3):181-91. PubMed ID: 20422473
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Cost-effectiveness of primary PTCA and thrombolysis in the treatment of acute myocardial infarction].
    Sagmeister M, Amann FW, Follath F.
    Schweiz Med Wochenschr; 2000 Aug 19; 130(33):1146-51. PubMed ID: 11005104
    [Abstract] [Full Text] [Related]

  • 40. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Thrombolytic therapy: economic considerations.
    Krumholz HM.
    Am Heart J; 1999 May 19; 137(5):S87-9. PubMed ID: 10220605
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.